Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

THURSDAY, Oct. 23, 2025 (HealthDay News) -- The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical ...

Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!

Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...